VIVA 23: PROMISE II: 12M Results From Pivotal Trial of LimFlow System

Published: 19 Dec 2023

  • Views:

    Views Icon 85
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

VIVA 23 - We are joined virtually by Dr Daniel Clair (Vanderbilt University Medical Center, US) in this short interview discussing the findings from the PROMISE II trial at 12 months.

The PROMISE II Trial aimed to investigate the safety and effectiveness of the LimFlow System in creating an arteriovenous connection in below the knee (BTK) vascular disease. The LimFlow System is intended to be used for minimally invasive endovascular procedures in patients with "no option" critical limb ischemia.

Interview Questions:

  1. What are the unmet needs for "no option" CLTI patients?
  2. What is the LimFlow system, and what are its unique features?
  3. What was the patient population and study design?
  4. What are your key findings at 12 months?
  5. What are your take-home messages?
  6. What further study is needed?

Recorded remotely from Tennessee, 2023.

Editor: Jordan Rance
Video Specialist: Oliver Miles


You must be to comment. If you are not registered, you can register here.